WASHINGTON — The Trump administration aforementioned Wednesday it is ending medical research by government man of sciences exploitation human fetal tissue, overriding the proposal of man of sciences that say there’s no other way to tackle some health problems and handing abortion opponents a major victory.
The Health and Human employment Department aforementioned in a statement that government-funded research by universities that involves fetal tissue can continue, subject to extra scrutiny.
The policy changes will not affect privately funded research, officials aforementioned.
Fetal tissue is used in research on HIV and childhood cancers, treatments that enlist the body’s immune system to battle cancer, and the hunt for a vaccine once once against the Zika virus, a cause of birth defects. The tissue from elective abortions would otherwise be discarded. Scientists use it to produce mice that model how the human immune system works.
Ending the use of fetal tissue by the National Institutes of Health has been a priority for anti-abortion activists, a core element of President Donald Trump’s political base.
The government’s top medical man of science, NIH Director Francis Collins, aforementioned as recently as last December that he believes “there’s strong evidence that scientific benefits come from fetal tissue research.”
A senior administration official aforementioned the decision announced Wednesday was the president’s call and not Collins’. The official spoke on condition of anonymity to discuss internal deliberations.
The government has funded research exploitation fetal tissue for decades, under administrations of some political parties.
The government aforementioned there are presently at least three active federal research projects that involve human fetal tissue, and possibly as galore as 12. Among university research projects funded by the government, officials aforementioned less than 200 of 50,000 trust on human fetal tissue.
No university-led programs will be affected for the time being, the administration aforementioned. New projects that propose to use fetal tissue and current projects up for renewal will be subject to extra reviews.
Last year, the administration announced a review of whether remunerator dollars were being properly spent on fetal tissue research. As a result, NIH froze procurement of new tissue. On Wednesday, the administration besides aforementioned it is not restorative an expiring contract with the University of California, San Francisco that involves fetal tissue research.
Although HHS aforementioned it was trying to balance “pro-life” and “pro-science” imperatives, medical investigators aforementioned they feared the government would halt important research to satisfy anti-abortion activists.
Kristan Hawkins, president of Students for Life of America, aforementioned in a statement that the administration has “once once once again done the right thing in restoring a culture of life to our government.”
The Susan B. Anthony List, a group that works to elect lawmakers opposed to abortion, aforementioned in a statement that remunerator funding ought to go to promoting alternatives to exploitation fetal tissue in medical research.
The groups say alternatives are available; scientific groups say that’s not the case for every unwellness and condition.
Trump casts himself as “strongly pro-life,” and his administration has taken galore steps to restrict access to abortion, which remains a legal medical procedure. Trump has nominative federal Judges who oppose abortion, unsuccessful to cut money for Planned parentage, and expanded legal protection for medical providers who object to abortion.
At a House hearing on the issue last December, neuroman of science Sally Temple told lawmakers the agreement opinion in the scientific community is that there is presently no adequate substitute for fetal tissue in some research areas.
- tracking microbes people carry may predict future health
- obesity surgery benefits may be bigger for teens than adults, CU researchers find
Temple explained that tissue samples from different stages of the life cycle are not interchangeable. “It is not the same material,” she aforementioned. “It is a different organic process stage. It has unique properties.” She was testifying on behalf of the International Society for Stem Cell Research.
Testifying on behalf of the Charlotte Lozier Institute, which opposes abortion, chemist Tara drum drum sander Lee aforementioned tissues from infants who have to have heart surgery are among the alternatives. But Temple aforementioned researchers would promptly use alternatives to fetal tissue if that was suitable.
Research involving fetal tissue accounted for $98 million in NIH grants and projects during the 2017 budget year, a small fraction of the agency’s overall research budget. NIH aforementioned that $98 million figure represents the entire budget for the grants at issue, even if only a smaller portion of a particular grant was devoted to fetal tissue research.
HHS aforementioned in its statement that is taking so much steps through a $20 million grant program announced last December to “develop, demonstrate, and validate experimental models that do not trust on human fetal tissue from elective abortions.”